Jellison T K, Mckinnon P S, Rybak M J
Department of Pharmacy Services, Detroit Receiving Hospital, Wayne State University, Michigan 48201, USA.
Pharmacotherapy. 2001 Feb;21(2):142-8. doi: 10.1592/phco.21.2.142.34114.
To evaluate epidemiology, resistance, and treatment outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam for 72 hours or longer.
Retrospective analysis.
University teaching hospital.
Forty-eight patients with A. baumannii bacteremia.
Evaluation of susceptibility and clinical data from 48 patients treated with either ampicillin-sulbactam or imipenem-cilastatin from 1987-1999.
Comparing ampicillin-sulbactam and imipenem-cilastatin, there were no differences between days of bacteremia (4 vs 2 days, p=0.05), days to resolution of temperature or white blood cell count, success or failure during or at end of treatment, or intensive care unit total or antibiotic-related length of stay (13 vs 10 days, p=0.05). Patients treated with ampicillin-sulbactam had significantly decreased antibiotic treatment costs (1500 dollars vs 500 dollars, p=0.004).
Ampicillin-sulbactam is at least as effective as imipenem-cilastatin based on clinical response at days 2, 7, and end of treatment and is a cost-effective alternative for treatment of A. baumannii infections.
评估用亚胺培南 - 西司他丁或氨苄西林 - 舒巴坦治疗72小时及以上的鲍曼不动杆菌血症的流行病学、耐药性及治疗结果。
回顾性分析。
大学教学医院。
48例鲍曼不动杆菌血症患者。
评估1987年至1999年期间接受氨苄西林 - 舒巴坦或亚胺培南 - 西司他丁治疗的48例患者的药敏情况和临床数据。
比较氨苄西林 - 舒巴坦和亚胺培南 - 西司他丁，在菌血症天数（4天对2天，p = 0.05）、体温或白细胞计数恢复正常的天数、治疗期间或结束时的成功或失败情况、重症监护病房总住院天数或抗生素相关住院天数（13天对10天，p = 0.05）方面无差异。接受氨苄西林 - 舒巴坦治疗的患者抗生素治疗费用显著降低（1500美元对500美元，p = 0.004）。
基于治疗第2天、第7天及治疗结束时的临床反应，氨苄西林 - 舒巴坦至少与亚胺培南 - 西司他丁一样有效，是治疗鲍曼不动杆菌感染的一种具有成本效益的替代药物。
